[W]hy does Meridian Bioscience continue to be a good investment? In short, the company continues to latch on to new opportunities. In early August, the company was awarded a five-year contract by the National Institutes of Health (NIH) to test and produce experimental viral vaccines. A few weeks later the company announced the start of phase 1 and 2 clinical trials for a vaccine aimed at preventing disease caused by parvovirus infections. These developments will help to shore up the company's life science business.